<strong>CCL2/CCR2 参与神经病理性疼痛的多靶点作用机制</strong>

摘要/Abstract

摘要：单核细胞趋化蛋白-1（monocyte chemoattractant protein-1，MCP-1，又称 CCL2）是最早发现的人类CC族趋化因子，对单核细胞趋化作用强，激发炎症与免疫反应。CCL2 及其受体CCR2（C-C chemokine receptor type 2）在疼痛发生和延续过程中扮演了重要角色。研究发现CCL2 能够由神经元分泌，作为神经调质参与疼痛过程，是引发神经病理性疼痛、免疫和炎症反应的共同介质。CCL2 在外周感觉传入神经、背根神经节、脊髓和延髓等不同水平参与神经病理性疼痛，易化痛觉传导。CCL2/CCR2 的痛觉调节机制包括神经病理性疼痛：①增加瞬时态电压感受器阳离子通道，子类V，成员1（transient receptor potential cation channel, subfamily V, member 1，TRPV1）电流幅度和通过PI3K/Akt 途径上调TRPV1 的mRNA 表达量；② CCL2 有可能激活PI3K/Akt 信号通路选择性上调Nav1.8 的mRNA 表达量，增加河豚毒素（tetrodotoxin，TTX）不敏感钠通道的电流幅度；③明显降低背根神经节神经元电压依赖性非失活钾电流，对不同神经病理性疼痛模型大鼠背根神经节中钾通道的作用存有差异；④加强N- 甲基-D- 天冬氨酸（N-methyl-D-aspartic acid，NMDA）和α- 氨基-3- 羟基-5- 甲基-4-异恶唑丙酸（α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor，AMPA）诱发的脊髓神经元内向电流，加强其自发性兴奋性突触后电流；⑤阿片受体与CCL2/CCR2 之间存在双向调节机制；⑥ CCL2 直接抑制神经元上的γ- 氨基丁酸（γ-aminobutyric acid，GABA）电流。

关键词:单核细胞趋化蛋白-1,单核细胞趋化蛋白-1 受体,神经病理性疼痛,离子通道,受体

Abstract:CCL2 is the first discovered human CC chemokine and a potent chemotactic factor for monocytes，which induces immunological and inflammatory response. CCL2 and its receptor CCR2 play a key role in development and maintainence of neuropathic pain. Study found that CCL2 can be produced by neurons，and CCL2 acts as a neuromodulator in the process of pain disorder. CCL2 is the common mediator of neuropathic pain，immunological and inflammatory response. CCL2 involves in neuropathic pain at different levels，including peripheral sensory afferent nerve，dorsal root ganglia and spinal cord，which facilitates pain transmission. CCL2/CCR2 regulates neuropathic pain based on the following mechanisms：①enhances current amplitude and levels of TRPV1 mRNA by upregulating PI3K/Akt pathway，②CCL2 selectively increases mRNA of Nav1.8 through activating PI3K/Akt pathway and enhancing amplitude of TTX-R current，③significantly decreases voltage dependent noninactivation potassium current （IK） in DRG neurons，and has different effects on potassium channel in DRG neurons from different NP animal models，④enhances NMDA and AMPA evoked currents in spinal cord neurons，and enhances their spontaneous excitatory postsynaptic currents （EPSCs），⑤there is a bidirectional regulation between opioid receptors and CCL2/CCR2，⑥CCL2 directly inhibits GABA current in neurons.

Key words:monocyte chemoattractant protein-1（CCL2),C-C chemokine receptor type2(CCR2),neuropathic pain,ion channel,receptor

中图分类号:

R965

李黎，张海林.CCL2/CCR2 参与神经病理性疼痛的多靶点作用机制[J]. 神经药理学报, 2016, 6(1): 49-57.

LI Li，ZHANG Hai-lin.The Multi-target Mechanism of CCL2/CCR2 Involved in Neuropathic Pain[J]. Acta Neuropharmacologica, 2016, 6(1): 49-57.

参考文献

[1] Ana Clara Cristovao, Dong-Hee Choi, Graca Baltazar, et al. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death[J]. Antioxid Redox Signal, 2009, 11(9): 2105-2118.

[2] Johanna Mäkelä, Timofey V Tselykh, Jyrki P Kukkonen, et al. Peroxisome proliferator-activated receptor-γ (PPARγ) agonist is neuroprotective and stimulates PGC-1α expression and CREB phosphorylation in human dopaminergic neurons[J]. Neuropharmacology, 2016, 102: 266-275.

[3] Nirit Lev, Yael Barhum, Neri S Pilosof, et al. DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging[J]. J Gerontol A Biol Sci Med Sci, 2013, 68(3): 215-225.

[4] Alvin P Joselin, Sarah J Hewitt, Steve M Callagham, et al. ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons[J]. Hum Mol Genet, 2012, 21(22): 4888-4903.

[5] Kazuki Hattori, Isao Naguro, Christopher Runchel, et al. The roles of ASK family proteins in stress responses and diseases[J]. Cell Commun Signal, 2009, 7: 9.

[6] Jens Waak, Stephanie Weber, Karin Gorner, et al. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1[J]. J Biol Chem, 2009, 284(21): 14245-57.

[7] Xiao Tao, Liang Tong. Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease[J]. J Biol Chem, 2003, 278(33): 31372-31379.

[8] Olga Corti, Suzanne Lesage, Alexis Brice. What genetics tells us about the causes and mechanisms of Parkinson's disease[J]. Physiol Rev, 2011, 91(4): 1161-1218.

[9] Hiromasa Ooe, Chinatsu Maita, Hiroshi Maita, et al. Specific cleavage of DJ-1 under an oxidative condition[J]. Neurosci Lett, 2006, 406(3): 165-168.

[10] Chen Jue, Li Lian, Chin Lih-shen. Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage[J]. Hum Mol Genet, 2010, 19(12): 2395-2408.

[11] N Kotaria, U Hinz, S Zechel, et al. Localization of DJ-1 protein in the murine brain[J]. Cell Tissue Res, 2005, 322(3): 503-507.

[12] Junn Eunsung, Won Hee Jang, Zhao-xin, et al. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection[J]. J Neurosci Res, 2009, 87(1): 123-129.

[13] V Bonifati, P Rizzu, F Squitieri, et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism[J]. Neurol Sci, 2003, 24(3): 159-160.

[14] Vincenzo Bonifati, Patrizia Rizzu, Marijke J Van Baren, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism[J]. Science, 2003, 299(5604): 256-259.

[15] Joungil Choi, M Cameron Sullards, James A Olzmann, et al. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases[J]. J Biol Chem, 2006, 281(16): 10816-10824.

[16] Dong Hwan Ho, Sanghak Yi, Hyemyung Seo, et al. Increased DJ-1 in urine exosome of Korean males with Parkinson's disease[J]. Biomed Res Int, 2014, 2014:704678.

[17] Kang Wen-yan, Yang Qiong, Jiang Xu-feng, et al. Salivary DJ-1 could be an indicator of Parkinson's disease progression[J]. Front Aging Neurosci, 2014, 6: 102.

[18] Masaaki Waragai, Masaaki Nakai, Jianshe Wei, et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease[J]. Neurosci Lett, 2007, 425(1): 18-22.

[19] Yoshiro Saito. Oxidized DJ-1 as a possible biomarker of Parkinson's disease[J]. J Clin Biochem Nutr, 2014, 54(3): 138-144.

[20] W Davis Parker, Janice K Parks, Russell H Swerdlow. Complex I deficiency in Parkinson's disease frontal cortex[J]. Brain Res, 2008, 1189: 215-218.

[21] C W Olanow. The pathogenesis of cell death in Parkinson's disease--2007[J]. Mov Disord, 2007, 22(Suppl 17): S335-S342.

[22] P Jenner. Oxidative stress in Parkinson's disease and other neurodegenerative disorders[J]. Pathol Biol (Paris), 1996, 44(1): 57-64.

[23] Philipp J Kahle, Jens Waak, Thomas Gasser. DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders[J]. Free Radic Biol Med, 2009, 47(10): 1354-1361.

[24] Hiroyoshi Ariga, Kazuko Takahashi, Izumi Kato, et al. Neuroprotective function of DJ-1 in Parkinson's disease[J]. Oxid Med Cell Longev, 2013, 2013: 683920.

[25] Rosa M Canet-Aviles, Mark A Wilson, David W Miller, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization[J]. Proc Natl Acad Sci USA, 2004, 101(24):9103-9108.

[26] Eunsung Junn, Hiroyuki Taniguchi, Byeong Seon Jeong, et al. Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death[J]. Proc Natl Acad Sci USA, 2005, 102(27): 9691-9696.

[27] Liu Fang, Jamie L Nguyen, John D Hulleman, et al. Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease[J]. J Neurochem, 2008, 105(6): 2435-53.

[28] Zhou Wen-bo, Curt R Freed. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity[J]. J Biol Chem, 2005, 280(52): 43150-43158.

[29] Derek A Drechsel, Manisha Patel. Respiration-dependent H2O2 removal in brain mitochondria via the thioredoxin/peroxiredoxin system[J]. J Biol Chem, 2010, 285(36): 27850-27858.

[30] Pamela Lopert, Manisha Patel. Brain mitochondria from DJ-1 knockout mice show increased respiration-dependent hydrogen peroxide consumption[J]. Redox Biology, 2014, 2:667-672.

[31] Casey M Clements, Richard S McNally, Brian J Conti, et al. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2[J]. Proc Natl Acad Sci USA, 2006, 103(41):15091-15096.

[32] Melba C Jaramillo, Donna D Zhang. The emerging role of the Nrf2-Keap1 signaling pathway in cancer[J]. Genes Dev, 2013, 27(20): 2179-2191.

[33] Li Gan, Delinda A Johnson, Jeffrey A Johnson. Keap1-Nrf2 activation in the presence and absence of DJ-1[J]. Eur J Neurosci, 2010, 31(6): 967-977.

[34] Tatsuki Yasuda, Yusuke Kaji, Tomohiro, et al. DJ-1 cooperates with PYCR1 in cell protection against oxidative stress[J]. Biochem Biophys Res Commun, 2013, 436(2):289-294.

[35] David Seo, Goldschmidt-Clemont P. The paraoxonase gene family and atherosclerosis[J]. Free Radic Biol Med, 2005, 38(2):153-163.

[36] Lucio G Costa, Rian de Laat, Khoi Dao, et al. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection[J]. Neurotoxicology, 2014, 43: 3-9.

[37] Jagan Mohan Jasna, Kannadasan Anandbabu, Subramaniam Rajesh Bharathi, et al. Paraoxonase enzyme protects retinal pigment epithelium from chlorpyrifos insult[J]. PLoS One, 2014, 9(6):e101380.

[38] Mohammad Parsanejad, Noam Bourquard, Dianbo Qu, et al. DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress[J]. PLoS One, 2014, 9(9): e106601.

[39] Rob M Ewing, Peter Chu, Fred Elisma, et al. Large-scale mapping of human protein-protein interactions by mass spectrometry[J]. Mol Syst Biol, 2007, 3(1):89.

[40] M D P Willcox, M Parsanejad, D W S Harty, et al. Regulation of the VHL/HIF-1 pathway by DJ-1[J]. J Neurosci, 2014, 34(23): 8043-8050.

[41] Xiong Ran, Wang Zhi-quan, Zhao Zong-bo, et al. MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration[J]. Neurobiol Aging, 2014, 35(3): 705-714.

CCL2/CCR2 参与神经病理性疼痛的多靶点作用机制

The Multi-target Mechanism of CCL2/CCR2 Involved in Neuropathic Pain

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

[1]	王思懿, 李现想, 刘宜周, 杜爽, 葛超, 刘斯斯.阿尔茨海默症治疗药物现状及展望[J]. 神经药理学报, 2020, 10(5): 38-42.
[2]	熊梦瑶, 贾英丽, 杨宝学.前列腺素受体4 与肾脏疾病相关性研究进展[J]. 神经药理学报, 2020, 10(3): 54-64.
[3]	焦苗苗, 王旭, 周娜, 张梦, 刘进娜, 谭展望, 黄东阳.延胡索、乌药、金铃子散、小活络丹对神经病理性疼痛镇痛作用的比较[J]. 神经药理学报, 2020, 10(2): 1-.
[4]	杨琳，艾静.脑源雌激素在阿尔茨海默病中的作用研究进展[J]. 神经药理学报, 2019, 9(5): 50-64.
[5]	吴县，洪浩.胆汁酸及其受体与中枢神经系统疾病[J]. 神经药理学报, 2019, 9(1): 23-30.
[6]	张丹参，苏晓梅.N- 甲基-D- 天冬氨酸受体在记忆网络中的作用[J]. 神经药理学报, 2019, 9(1): 44-62.
[7]	张帅，艾静.谷氨酸功能异常与阿尔茨海默病[J]. 神经药理学报, 2018, 8(6): 9-20.
[8]	SHEN li-xia1，LIU Liang-liang1，ZHANG Ming1，LIU Yang1，ZHANG Dan-shen 2*.Research of Quercetin’s Estrogen-Like Action on Central Nervous System and Its Mechanisms[J]. 神经药理学报, 2018, 8(4): 23-25.
[9]	孙毅，谭博，苏瑞斌.偏向性配体——阿片类镇痛药设计新思路[J]. 神经药理学报, 2018, 8(2): 1-7.
[10]	刘双，李小慧，高健美，刘远贵，石京山，龚其海.磷酸二酯酶5 抑制剂淫羊藿次苷II 通过BDNF/TrkB/CREB 信号通路减轻淀粉样蛋白25-35 片段诱导的大鼠学习记忆减退作用及机制研究[J]. 神经药理学报, 2018, 8(2): 44-44.
[11]	王静，程肖蕊，周文霞，张永祥.快速老化模型小鼠海马囊泡谷氨酸转运体表达与兴奋性毒性关系的研究[J]. 神经药理学报, 2018, 8(2): 53-53.
[12]	王允，镇学初.新型Sigma-1 受体变构调节剂的发现和潜在应用[J]. 神经药理学报, 2018, 8(1): 35-44.
[13]	昝桂影,孙翔，李庆林，刘景根 .κ阿片受体在抑郁中的作用及机制研究进展[J]. 神经药理学报, 2018, 8(1): 54-64.
[14]	武亚茹，常可欣，贾庆忠.神经病理性疼痛动物模型的制备与评价方法[J]. 神经药理学报, 2017, 7(5): 15-.
[15]	侯文书，张力.中药有效成分治疗阿尔茨海默病的作用靶点研究进展[J]. 神经药理学报, 2017, 7(5): 59-64.